Healthcare: Exelixis Nets a Win and Colorado Takes Aim at Health Insurers *** INDUSTRY FOCUS ***

TL;DR

Exelixis gains approval for its new drug combination in the US, while Colorado prepares for a single-payer healthcare system.

Transcript

Kristine Harjes: The Swiss are on the offensive against cancer. This is Industry Focus. Harjes: Hi everyone! Welcome to the healthcare edition of Industry Focus. I’m your host Kristine Harjes. And we’ve got Todd Campbell on the show via Skype. Our regular healthcare contributor. Todd, how’s it going? Todd Campbell: Good! How are you? Harjes: Pretty... Read More

Key Insights

• ✋ Exelixis' new drug combo approval provides a significant advancement in melanoma treatment options, but the high cost may pose challenges in market adoption.
• 😮 The single-payer healthcare system proposed in Colorado seeks to address rising insurance premiums but may have significant implications on the healthcare industry and taxes.

Questions & Answers

Q: What is the significance of the approval of Exelixis' new drug combo?

The approval of COTELLIC and ZELBORAF provides a new treatment option for patients with advanced melanoma, improving response rates and delaying disease progression.

Q: How much will the new drug combo cost?

The estimated cost of the new drug combo is $17,500 per month, which may impact its market share in a competitive field, particularly considering the rising prices of cancer drugs.

Q: What are the potential implications of Colorado's single-payer healthcare system?

The single-payer system could potentially reduce insurance premiums but would increase taxes to cover healthcare costs. It may also impact the insurance industry and job market in the healthcare sector.

Q: What are the challenges and uncertainties surrounding the implementation of a single-payer system?

The costs of healthcare expenses, such as drug prices and doctor salaries, are likely to continue to rise, potentially leading to higher taxes. The impact on various stakeholders, including insurance companies and healthcare professionals, remains uncertain.

Summary & Key Takeaways

• Exelixis' new drug combo, COTELLIC and ZELBORAF, has been approved to treat advanced melanoma, boosting overall response rates from 50% to 70% and delaying disease progression.

• The cost of the new drug combo is estimated to be around $17,500 per month, which may impact its market share in a competitive field.

• Colorado is preparing to vote on a proposal for a single-payer healthcare system, aiming to reduce insurance premiums but increasing taxes to cover healthcare costs.